Belatacept: a new biological agent for maintenance immunosuppression in kidney transplantation

Bibliography

• Wolfe R, Ashby V, Milford E, Comparison of mortality in all patients on dialysis, Patients on dialysis awaiting transplantation, recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-30
   PubMed Web of Science ®Google Scholar
• Schnuelle P, Lorenz D, Trede M, Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long term follow up. J Am Soc Nephrol 1998;9(11):2135
   PubMed Web of Science ®Google Scholar
• Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients Annual report. Table 1.11b. Available from: http://www.ustransplant.org/FastFacts.aspx# [Accessed 2 January 2012]
   Google Scholar
• Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in United States: a critical reappraisal. Am J Transplant 2010;11(10):2264-5
   Google Scholar
• Meier-Kriesche HU, Schold JD, Srinivas TR. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4(3):378
   PubMed Web of Science ®Google Scholar
• Nankivelli BJ, Borrows RJ, Fung CL, The natural history of chronic allograft nephropathy. N Engl J Med 2003;349(24):2326-33
   PubMedGoogle Scholar
• Kaplan B, Budde K. Lessons from the CAESAR study: calcineurin inhibitors- can't live with them and can't live without them. Am J Transplant 2007;7(3):495-6
   PubMed Web of Science ®Google Scholar
• Gaston RS, Cecka JM, Kasiske BL, Evidence for antibody- mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010;90:68
   PubMed Web of Science ®Google Scholar
• Stegall MD, Park WD, Larson TS, The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011;11(4):698-707
   PubMed Web of Science ®Google Scholar
• Rapamune Package Insert. 5.12. De novo use of Rapamune without Cyclosporine
   Google Scholar
• Flechner SM, Glyda M, Cockfiled S, The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011;11(8):1633-4
   PubMed Web of Science ®Google Scholar
• Ekberg H, Bernasconi C, Noldeke J, Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the symphony study. Nephrol Dial Transplant 2010;25(6):2004-10
   PubMed Web of Science ®Google Scholar
• Budde K, Becker T, Arns W, Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011;377:837-47
   PubMed Web of Science ®Google Scholar
• Ekberg H, Grinyo J, Nashan B, Cyclosporin sparing with mycophenolate mofetil daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007;7:560-70
   PubMed Web of Science ®Google Scholar
• Vincenti F, Ramos E, Brattstrom C, Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001;71:1282-7
   PubMed Web of Science ®Google Scholar
• OPTN/SRTR Data as of October 1, 2010
   Google Scholar
• Cooper JE, Wiseman AC. Novel immunosuppressive agents in kidney transplantation. Clin Nephrol 2010;73(5):333-43
   PubMed Web of Science ®Google Scholar
• Halloran PF. Immunosuppresive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29
   PubMed Web of Science ®Google Scholar
• Martin S, Tichy E, Gabardi S. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy 2011;31(4):394-407
   PubMed Web of Science ®Google Scholar
• Weisman MH, Durez P, Hallegua D, Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006;33:2162-6
   PubMed Web of Science ®Google Scholar
• Larsen CP, Pearson TC, Adams AB, Rational development of LEA 29Y (belatacept), a high- affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005;5(3):443-53
   PubMed Web of Science ®Google Scholar
• Latek R, Fleener C, Lamian V, Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009;87(6):926-33
   PubMed Web of Science ®Google Scholar
• Nulojix® Package Insert, June 2011
   Google Scholar
• Zhou Z, Shen J, Kaul S, Belatacept population pharmacokinetics in renal transplant patients [abstract 1501]. Abstract presented at American Transplant Congress; May 2010.
   Google Scholar
• Shen J, Block R, Townsend X, Pharmacokinetics, pharmacodynamics and immunogenicity of belatacept in renal transplant patients [abstract 187026]. American transplant congress; May 2010
   Google Scholar
• Latek R, Fleener C, Lamian V, Assessment of belatacept mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009;87:926-933s
   PubMed Web of Science ®Google Scholar
• Vincenti F, Blancho G, Durrbach A, Five-year safety and efficacy of Belatacept in renal transplantation. Clin J Am Soc Nephrol 2010;21:1587-96
   Web of Science ®Google Scholar
• Vincenti F, Larsen C, Durrbach A, Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-81
   PubMed Web of Science ®Google Scholar
• Vincent F, Charpentier B, Vanrenterghem Y, A phase III study of Belatacept-based immunosuppression regimes versus Cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant 2010;10(3):535-46
   PubMed Web of Science ®Google Scholar
• Durrback A, Pestana JM, Pearson T, A phase III study of Belatacept versus Cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study). Am J Transplant 2010;10:547-57
   PubMed Web of Science ®Google Scholar
• Larsen C, Grinyo J, Medina-Pestana J, Belatacept-based regimens versus a Cyclosporine A-based regimen in kidney transplant recipients: 2-Year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010;90:1528-35
   PubMed Web of Science ®Google Scholar
• Pestana JO, Grinyo JM, Vanrenterghem Y, Three-year outcomes from BENEFIT-EXT: a phase iii study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012;12(3):630-9
   PubMed Web of Science ®Google Scholar
• Rostaing L, Neumayer HH, Reyes-Acevedo R, Belatacept-versus Cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. Clin J Am Soc Nephrol 2011;6:2696-704
   PubMed Web of Science ®Google Scholar
• Florman S, Bresnahan B, Chan L, Three year outcomes in Black/African American kidney transplant recipients from BENEFIT and BENEFIT-EXT studies [abstract 1091]. Am Transplant Congress; Apr – May 2011
   Google Scholar
• Dobbles F, Wong S, Joo S, Kalsekar A. Health-related quality of life after kidney transplantation: Results from Belatacept clinical trials [abstract 1099]. Am Transplant Congress; Apr – May 2011
   Google Scholar
• Dobbles F, Wong S, You M and Kalsekar A. Patient reports of immunosuppressant related side-effects after kidney transplantation: results from the Belatacept phase III clinical trial (BENEFIT) [abstract 1100]. Am Transplant Congress; Apr – May 2011
   Google Scholar
• Larsen C, Bray R, Howard G, Evaluation of donor-specific antibodies in kidney transplant with belatacept or cyclosporine based immunosuppression in BENEFIT and BENEFIT-EXT [abstract O-244]. Am Transplant Congress; Apr – May 2011
   Google Scholar
• Ferguson R, Grinyo J, Vincenti F, Immunosuppression with Belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011;11:66-76
   PubMed Web of Science ®Google Scholar
• Rostaing L, Massari P, Garcia VD, Switching from calcineurin inhibitor-based regimens to a Belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011;6:430-9
   PubMed Web of Science ®Google Scholar
• Grinyo J, Nainan G, Rial M, Renal function at 2 years in kidney transplant recipients switched from Cyclosporine or Tacrolimus to Belatacept: results from the long-term extension of a phase II study [abstract 226]. Am Transplant Congress; Apr – May 2011
   Google Scholar
• Bestard O, Cassis L, Cruzado JM, Costimulatory blockage with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Eur Soc Organ Transpl 2011;24:451-60
   PubMedGoogle Scholar
• Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 2008;121:307-8
   Web of Science ®Google Scholar
• Bluestone JA. CTLA-4I g is finally making it: a personal perspective. Am J Transplant 2005;5:423
   PubMed Web of Science ®Google Scholar
• Bestard O, Cruzado JM, Mestre M, Achieving donor specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007;179:4901
   PubMed Web of Science ®Google Scholar
• Noris M, Casiraghi F, Todeschini M, Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007;18:1007
   PubMed Web of Science ®Google Scholar
• Joffre O, Santolaria T, Calise D, Prevention of acute and chronic allograft rejection with CD4+CD25+FoxP3+ regulatory T lymphocytes. Nat Med 2008;14:88
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Liu W, Yabu JM, The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008;8:2086-96
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perico N, Gotti E, Sirolimus versus Cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given Alemtuzumab induction from chronic allograft injury. Transplantation 2007;84:956
   PubMed Web of Science ®Google Scholar
• Kirk AD, Mead S, Xu H, Kidney transplantation using alemtuzumab induction and belatacept/sirolimus maintenance therapy [abstract 56]. Am Transplant Congress; Apr – May 2011
   Google Scholar
• Grinyo J, Charpentier B, Pestana JM, An integrated safety profile analysis of Belatacept in kidney transplant recipients. Transplantation 2010;90:1521-7; 51
   PubMed Web of Science ®Google Scholar
• Diaz JM, Gich I, Bonfill X, Prevalence evolution and impact of cardiovascular risk factors on allograft and renal transplant patient survival. Transplant Proc 2009;41:2151
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Bresnahan B, Campistol J, Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with Cyclosporine in kidney transplant Recipients (BENEFIT and BENEFIT-EXT Studies). Transplantation 2011;91:976-83
   PubMed Web of Science ®Google Scholar
• Pirsch JD, Miller J, Deierhoi MH, A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997;63(7):977-83
   PubMed Web of Science ®Google Scholar
• Kramer BK, Montagnino G, Del Castillo D, Efficacy and safety of tacrolimus compared with cyclosporine A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005;20(5):968-73
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357(25):2562-75
   PubMed Web of Science ®Google Scholar
• Cheung CY, Chan HW, Liu YL, Long-term graft function with tacrolimus and cyclosporine in renal transplantation: paired kidney analysis. Nephrology (Carlton) 2009;14(8):758-63
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B; Collaborative Transplant Study. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009;87(6):795-802
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Pharmacokinetics, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects. ClinicalTrials.gov; NCT00569803. www.bms.com [Accessed 2 January 2012]
   Google Scholar
• Libertiny G, Watson CJ, Gray DW, Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001;88:1330-4
   PubMed Web of Science ®Google Scholar
• Caillard S, Dharnidharka V, Agodoa L, Post-transplant Lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005;80:1233-43
   PubMed Web of Science ®Google Scholar
• Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005;80:193-7
   PubMed Web of Science ®Google Scholar